Scancell, the Nottingham based cancer vaccine developer, announced final results to April 2011 showing a pre-tax loss of £1.7 million (2010: £1.8 million) and that year end net cash was £1.1 million. The company has raised £1.73 million via a private placing (subject to shareholder approval) at 5p per share in exchange for shares representing 17.8% of the enlarged share capital.

In addition, Scancell announced that it has generated encouraging data in an animal model for lung cancer with its new SCIB2 vaccine. SCIB2 may also have utility in treating oesophageal, liver, gastric, prostate, ovarian and bladder cancers. Dr Richard Goodfellow has become joint-CEO, with responsibilities including the commercial activities, investor and City liaison, and management of the Company's exit strategy.

The SCLP share price has decreased by 15% over the last six months.

Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here